RISK OF MALIGNANCY IN THYROID CYTOLOGY: THE IMPACT OF THE RECLASSIFICATION OF NONINVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES (NIFTP)

2019 ◽  
Vol 25 (7) ◽  
pp. 642-647 ◽  
Author(s):  
Mara Ventura ◽  
Miguel Melo ◽  
Graça Fernandes ◽  
Francisco Carrilho
Keyword(s):  
Thyroid Neoplasm ◽  
Thyroid Cytology ◽  
Risk Of Malignancy ◽  
The Impact ◽  
Nuclear Features

scholarly journals Noninvasive follicular thyroid neoplasm with papillary-like nuclear features and the risk of malignancy in thyroid cytology: Data from Singapore

2021 ◽  
Vol 50 (12) ◽  
pp. 903-910
Author(s):  
Bryan Wei Wen Lee ◽  
Manish Mahadeorao Bundele ◽  
Rong Tan ◽  
Ernest Wei Zhong Fu ◽  
Agnes Siqi Chew ◽  
...  
Keyword(s):  
Distant Recurrence ◽  
Needle Aspiration ◽  
Thyroid Neoplasm ◽  
Thyroid Cytology ◽  
Risk Of Malignancy ◽  
Needle Aspiration Cytology ◽  
Thyroid Cytopathology ◽  
The Impact ◽  
Nuclear Features

Introduction: The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on the risk of malignancy (ROM) in fine-needle aspiration cytology (FNAC) per The Bethesda System for Reporting Thyroid Cytopathology has not been well reported in Singapore. Methods: We retrospectively identified 821 thyroid nodules with preoperative FNAC from 788 patients out of 1,279 consecutive thyroidectomies performed between January 2010 and August 2016 in a tertiary general hospital in Singapore. Possible cases of NIFTP were reviewed for reclassification and the impact of NIFTP on ROM was analysed. Results: The incidence of NIFTP was 1.2% (10 out of 821). If NIFTP is considered benign, ROM in Bethesda I through VI were 8.6%, 3.5%, 26.3%, 20.0%, 87.7%, 97.0% versus 8.6%, 4.2%, 28.1%, 26.7%, 89.2% and 100% if NIFTP is considered malignant. Eight patients with NIFTP had follow-up of 15 to 110 months. One had possible rib metastasis as evidenced by I131 uptake but remained free of structural or biochemical disease during a follow-up period of 110 months. None had lymph node metastasis at presentation, nor locoregional or distant recurrence. Conclusion: Classifying NIFTP as benign decreased ROM in Bethesda II through VI, but the benignity of NIFTP requires more prospective studies to ascertain. The impact of NIFTP on ROM in our institution also appears to be lower than that reported in the Western studies Keywords: Bethesda, cytology, NIFTP, risk of malignancy, TBSRTC, thyroid nodule

scholarly journals Risk of Malignancy in Thyroid Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System in the NIFTP Era

2018 ◽  
Vol 50 (10) ◽  
pp. 735-737 ◽  
Author(s):  
Pedro Rosario ◽  
Alexandre da Silva ◽  
Maurício Nunes ◽  
Michelle Borges
Keyword(s):  
Thyroid Nodules ◽  
Data System ◽  
Thyroid Neoplasm ◽  
Malignant Tumours ◽  
Thyroid Imaging ◽  
Risk Of Malignancy ◽  
Nuclear Features

AbstractRecently, the American College of Radiology (ACR) proposed a Thyroid Imaging Reporting and Data System (TI-RADS) for thyroid nodules based on ultrasonographic features. It is important to validate this classification in different centres. The present study evaluated the risk of malignancy in solid nodules>1 cm using ACR TI-RADS. The risk of malignancy was defined including noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and after its exclusion from malignant tumours. For the present study, the original images were revised, and each nodule was assigned to one of the TI-RADS levels proposed for solid nodules: TR3, TR4, or TR5. This risk of malignancy was significantly different for the three levels: 1.7%, 11.2%, and 60.6% for TR3, TR4, and TR5, respectively, when NIFTP was included, and 0.6%, 7.9%, and 60.2% for TR3, TR4, and TR5, respectively, when NIFTP was excluded from malignant tumours. The nodules corresponding to NIFTP were classified according to ACR as TR3 in 28.5% of cases, TR4 in 67.8%, and TR5 in only 3.5%. The nodules corresponding to cancer were classified according to ACR as TR3 in only 2.3% of cases, TR4 in 27%, and TR5 in 70.5%. In conclusion, this study shows the validity of the ACR TI-RADS for solid thyroid nodules, even after the exclusion of NIFTP from malignant tumours.

Sign in / Sign up

Export Citation Format

Share Document